



## Konstanze Döhner

### Kontakt

Konstanze Döhner

## Publikationen (8)

Scotch A, Kosiorek H, Scherber R, Dueck A, Slot S, Zweegman S, Boekhorst P, Commandeur S, Schouten H, Sackmann F, Fuentes A, Hernández-Maraver D, Pahl H, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J, Ranta D, Roy L, Cahn J, Harrison C, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson P, Barbui T, Barosi G, Vannucchi A, Paoli C, Passamonti F, Andreasson B, Ferrari M, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian J, Zhang P, Gale R, Mesa R, Geyer H. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. *Leuk Res* 2017; 63:34-40.

Geyer H, Kosiorek H, Dueck A, Scherber R, Slot S, Zweegman S, Te Boekhorst P, Senyak Z, Schouten H, Sackmann F, Fuentes A, Hernández-Maraver D, Pahl H, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J, Ranta D, Roy L, Cahn J, Harrison C, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson P, Barbui T, Barosi G, Vannucchi A, Paoli C, Passamonti F, Andreasson B, Ferrari M, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian J, Zhang P, Gale R, Mesa R. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. *Haematologica* 2016; 102:85-93.

Geyer H, Scherber R, Kosiorek H, Dueck A, Kiladjian J, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes A, Hernández-Maraver D, Döhner K, Harrison C, Radia D, Muxi P, Besses C, Cervantes F, Johansson P, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J, Ranta D, Roy L, Cahn J, Maldonado N, Barosi G, Ferrari M, Gale R, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst P, Commandeur S, Schouten H, Pahl H, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi A, Passamonti F, Samuelsson J, Mesa R. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. *J Clin Oncol* 2015; 34:151-9.

Schittenhelm M, Illing B, Ahmut F, Rasp K, Blumenstock G, Döhner K, Lopez C, Kampa-Schittenhelm K. Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure. *PLoS one* 2013; 8:e80193.

Kampa-Schittenhelm K, Heinrich M, Akmut F, Rasp K, Illing B, Döhner H, Döhner K, Schittenhelm M. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. *Mol Cancer* 2013; 12:46.

Krönke J, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk R, Döhner H, Späth D, Kapp-Schwörer S, Bullinger L, Teleanu V, Tschürtz F, Gaidzik V, Kühn M, Rucker F, Holzmann K, Paschka P, Döhner K. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. *Blood* 2013; 122:100-8.

Kampa-Schittenhelm K, Heinrich M, Akmut F, Döhner H, Döhner K, Schittenhelm M. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. *Mol Cancer* 2013; 12:19.

Fröhling S, Jiang J, Schittenhelm M, Lee B, Griffin J, Stone R, Heinrich M, Deininger M, Druker B, Golub T, Teckie S, Ebert B, Scholl C, Levine R, Loriaux M, Boggon T, Bernard O, Berger R, Döhner H, Döhner K, Gilliland D. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. *Cancer Cell* 2007; 12:501-13.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)